Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Cingulate Inc. stock logo
CING
Cingulate
$4.51
+7.4%
$4.05
$1.80
$20.83
$19.15M-0.851.10 million shs149,999 shs
Hookipa Pharma Inc stock logo
HOOK
Hookipa Pharma
$1.48
+4.2%
$1.24
$0.72
$7.55
$18.04M0.9682,003 shs75,192 shs
Longeveron Inc. stock logo
LGVN
Longeveron
$1.29
-0.8%
$1.41
$1.14
$6.40
$19.26M0.221.50 million shs101,317 shs
Xenetic Biosciences Inc stock logo
XBIO
Xenetic Biosciences
$2.79
-7.3%
$2.85
$2.20
$5.20
$4.30M2.2813,515 shs16,270 shs
The 10 Best AI Stocks to Own in 2025 Cover

Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Cingulate Inc. stock logo
CING
Cingulate
0.00%-3.67%+9.95%+13.51%+535.30%
Hookipa Pharma Inc stock logo
HOOK
Hookipa Pharma
0.00%-8.97%-8.97%+19.33%-80.90%
Longeveron Inc. stock logo
LGVN
Longeveron
0.00%+5.69%-8.45%-24.42%-59.25%
Xenetic Biosciences Inc stock logo
XBIO
Xenetic Biosciences
0.00%+1.14%+6.87%-15.26%-19.43%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Cingulate Inc. stock logo
CING
Cingulate
2.2805 of 5 stars
3.52.00.00.03.10.80.6
Hookipa Pharma Inc stock logo
HOOK
Hookipa Pharma
3.1395 of 5 stars
3.25.00.00.03.31.70.6
Longeveron Inc. stock logo
LGVN
Longeveron
3.4995 of 5 stars
3.65.00.00.02.01.71.3
Xenetic Biosciences Inc stock logo
XBIO
Xenetic Biosciences
1.9626 of 5 stars
0.05.00.00.03.30.81.3
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Cingulate Inc. stock logo
CING
Cingulate
3.00
Buy$26.00476.50% Upside
Hookipa Pharma Inc stock logo
HOOK
Hookipa Pharma
2.33
Hold$4.50204.05% Upside
Longeveron Inc. stock logo
LGVN
Longeveron
3.25
Buy$8.67571.83% Upside
Xenetic Biosciences Inc stock logo
XBIO
Xenetic Biosciences
2.00
HoldN/AN/A

Current Analyst Ratings Breakdown

Latest XBIO, CING, HOOK, and LGVN Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
5/27/2025
Cingulate Inc. stock logo
CING
Cingulate
Ascendiant Capital Markets
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$60.00 ➝ $61.00
5/19/2025
Cingulate Inc. stock logo
CING
Cingulate
Roth Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Set Price TargetBuy ➝ Buy$12.00 ➝ $11.00
4/21/2025
Cingulate Inc. stock logo
CING
Cingulate
Ascendiant Capital Markets
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$75.00 ➝ $60.00
4/9/2025
Xenetic Biosciences Inc stock logo
XBIO
Xenetic Biosciences
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingNeutral ➝ Neutral
3/21/2025
Longeveron Inc. stock logo
LGVN
Longeveron
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$10.00 ➝ $10.00
3/20/2025
Xenetic Biosciences Inc stock logo
XBIO
Xenetic Biosciences
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingNeutral ➝ Neutral
(Data available from 6/16/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Cingulate Inc. stock logo
CING
Cingulate
N/AN/AN/AN/A($70.63) per shareN/A
Hookipa Pharma Inc stock logo
HOOK
Hookipa Pharma
$9.35M1.93N/AN/A$9.08 per share0.16
Longeveron Inc. stock logo
LGVN
Longeveron
$2.23M8.65N/AN/A$2.68 per share0.48
Xenetic Biosciences Inc stock logo
XBIO
Xenetic Biosciences
$2.58M1.67N/AN/A$6.36 per share0.44
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Cingulate Inc. stock logo
CING
Cingulate
-$23.53M-$8.48N/AN/AN/AN/A-570.20%-236.15%8/12/2025 (Estimated)
Hookipa Pharma Inc stock logo
HOOK
Hookipa Pharma
-$81.58M-$5.85N/AN/AN/A-86.74%-33.31%-21.65%8/6/2025 (Estimated)
Longeveron Inc. stock logo
LGVN
Longeveron
-$21.41M-$6.28N/AN/AN/A-967.49%-142.43%-100.84%8/13/2025 (Estimated)
Xenetic Biosciences Inc stock logo
XBIO
Xenetic Biosciences
-$4.14M-$2.38N/AN/AN/A-161.63%-49.51%-43.99%8/12/2025 (Estimated)

Latest XBIO, CING, HOOK, and LGVN Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/15/2025Q1 2025
Hookipa Pharma Inc stock logo
HOOK
Hookipa Pharma
-$0.61-$1.23-$0.62-$1.23$3.38 millionN/A
5/13/2025Q1 2025
Xenetic Biosciences Inc stock logo
XBIO
Xenetic Biosciences
-$0.72-$0.59+$0.13-$0.59$0.52 million$0.59 million
5/8/2025Q1 2025
Cingulate Inc. stock logo
CING
Cingulate
-$1.00-$1.04-$0.04-$1.04N/AN/A
3/18/2025Q4 2024
Xenetic Biosciences Inc stock logo
XBIO
Xenetic Biosciences
-$0.20-$0.68-$0.48-$0.68$0.18 million$0.65 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Cingulate Inc. stock logo
CING
Cingulate
N/AN/AN/AN/AN/A
Hookipa Pharma Inc stock logo
HOOK
Hookipa Pharma
N/AN/AN/AN/AN/A
Longeveron Inc. stock logo
LGVN
Longeveron
N/AN/AN/AN/AN/A
Xenetic Biosciences Inc stock logo
XBIO
Xenetic Biosciences
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Cingulate Inc. stock logo
CING
Cingulate
N/A
7.35
7.35
Hookipa Pharma Inc stock logo
HOOK
Hookipa Pharma
N/A
3.26
3.26
Longeveron Inc. stock logo
LGVN
Longeveron
N/A
7.67
7.67
Xenetic Biosciences Inc stock logo
XBIO
Xenetic Biosciences
N/A
6.97
6.97

Institutional Ownership

CompanyInstitutional Ownership
Cingulate Inc. stock logo
CING
Cingulate
41.31%
Hookipa Pharma Inc stock logo
HOOK
Hookipa Pharma
63.88%
Longeveron Inc. stock logo
LGVN
Longeveron
10.01%
Xenetic Biosciences Inc stock logo
XBIO
Xenetic Biosciences
15.12%

Insider Ownership

CompanyInsider Ownership
Cingulate Inc. stock logo
CING
Cingulate
5.27%
Hookipa Pharma Inc stock logo
HOOK
Hookipa Pharma
3.30%
Longeveron Inc. stock logo
LGVN
Longeveron
11.20%
Xenetic Biosciences Inc stock logo
XBIO
Xenetic Biosciences
14.70%
CompanyEmployeesShares OutstandingFree FloatOptionable
Cingulate Inc. stock logo
CING
Cingulate
204.25 million2.66 millionNot Optionable
Hookipa Pharma Inc stock logo
HOOK
Hookipa Pharma
5612.19 million11.66 millionOptionable
Longeveron Inc. stock logo
LGVN
Longeveron
2014.93 million12.00 millionNot Optionable
Xenetic Biosciences Inc stock logo
XBIO
Xenetic Biosciences
41.54 million1.32 millionNot Optionable

Recent News About These Companies

Xenetic Biosciences (XBIO) Receives a Hold from H.C. Wainwright

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
Cingulate stock logo

Cingulate NASDAQ:CING

$4.51 +0.31 (+7.38%)
Closing price 04:00 PM Eastern
Extended Trading
$4.72 +0.22 (+4.77%)
As of 04:28 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Cingulate Inc., a biopharmaceutical company, focuses on the development of pharmaceutical products for the treatment of attention deficit/hyperactivity disorder and anxiety in the United States. The company's stimulant medications are CTx-1301 (dexmethylphenidate), which is in phase 3 clinical trial, as well as CTx-1302 (dextroamphetamine), which is in investigational new drug application development for the treatment of attention deficit/hyperactivity disorder intended for children, adolescents, and adults. It also focuses on developing CTx-2103 that is in a formulation stage for the treatment of anxiety. The company was founded in 2012 and is headquartered in Kansas City, Kansas.

Hookipa Pharma stock logo

Hookipa Pharma NASDAQ:HOOK

$1.48 +0.06 (+4.23%)
Closing price 04:00 PM Eastern
Extended Trading
$1.46 -0.01 (-1.01%)
As of 04:04 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

HOOKIPA Pharma Inc., a clinical-stage biopharmaceutical company, develops immunotherapeutics targeting infectious diseases and cancers based on its proprietary arenavirus platform. The company's lead infectious disease product candidate is HB-101, which is in a randomized double-blinded Phase 2 clinical trial in cytomegalovirus-negative patients awaiting kidney transplantation from cytomegalovirus-positive donors. Its lead oncology product candidates are HB-201 and HB-202 that are in preclinical studies for the treatment of human papillomavirus-positive cancers. The company has a collaboration with Gilead Sciences, Inc. to develop arenavirus based therapeutics to treat hepatitis B virus and human immunodeficiency virus infections. HOOKIPA Pharma Inc. was founded in 2011 and is headquartered in New York, New York.

Longeveron stock logo

Longeveron NASDAQ:LGVN

$1.29 -0.01 (-0.77%)
Closing price 04:00 PM Eastern
Extended Trading
$1.32 +0.03 (+2.33%)
As of 04:16 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Longeveron Inc., a clinical stage biotechnology company, develops cellular therapies for aging-related and life-threatening conditions in the United States and Japan. The company's lead investigational product is the LOMECEL-B, an allogeneic mesenchymal stem cell formulation sourced from the bone marrow of young and healthy adult donors. It is conducting Phase 1, Phase 1/2, Phase 2a, and Phase 2b clinical trials in various indications, such as aging-related frailty, alzheimer's disease, and hypoplastic left heart syndrome. Longeveron Inc. was incorporated in 2014 and is headquartered in Miami, Florida.

Xenetic Biosciences stock logo

Xenetic Biosciences NASDAQ:XBIO

$2.79 -0.22 (-7.31%)
As of 04:00 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Xenetic Biosciences, Inc. is a biopharmaceutical company focused on progressing XCART, a personalized CAR T platform technology engineered to target patient-specific tumor neoantigens. The Company is initially advancing cell-based therapeutics targeting the unique B-cell receptor on the surface of an individual patient's malignant tumor cells for the treatment of B-cell lymphomas. XCART has the potential to fuel a robust pipeline of therapeutic assets targeting high-value oncology indications.